All In Biotech

Drug Trial Radar · NCT00996983

Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer

Last checked: Nov 20, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

16

Planned (sponsor's estimate)

Start

Sep 2009

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
National Cancer Institute, NaplesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.

Conditions

  • Pain
  • Neuropathic Pain
  • Intractable Pain
  • Cancer

Interventions

  • ziconotideDrug

    intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rate (> 30% reduction in VASPI)Time frame: 48 hours after completion of titration phase

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Istituto Nazionale dei Tumori , Unita Terapia Antalgica

    Naples, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.